1. MENTAL HEALTH CARE REFORM IN LITHUANIA: THE MAIN TRENDS AND FINANCING
Ona Davidonienė
State Mental Health Centre

2. MENTAL DISORDERS IN LITHUANIA (per 100 000)
Data of State Mental Health Centre of Lithuania

3. SUICIDES IN LITHUANIA 1930-1940 AND 1986-2001 (per 100 000)

4. SUICIDES IN URBAN AND RURAL AREAS IN LITHUANIA 1930-1940 AND 1980-2001 (per 100 000)

5. GROWTH OF DRUG ADDICTION MORBIDITY IN LITHUANIA (per 100 000)
Data of State Mental Health Centre of Lithuania

6. MENTAL HEALTH CARE REFORM
Pre-reform state
Reform target
In-patient
treatment
In-patient
treatment
Reform
Outpatient
treatment
Outpatient
treatment

7. MENTAL HEALTH ACTS AND PROGRAMMES
Mental Health Care Act (1995) (
(Amendments made in 2001).
Narcotic and Psychotropic Substances Control Act (1998) (
State Programme on Mental Disease Prevention (1999) (
National Drug Control and Drug Use Prevention Programme (approved in 1999).
State Alcohol Control Programme (approved in 1999).

8. MENTAL HEALTH CENTRES STAFF IN LITHUANIA
1 January, 1999
1 January, 2000
1 January, 2001
1 January, 2002 49 55 59 61
Specialists for mental health
Psychiatrists
102,25
105,5
117,25
123,0
Child psychiatrists
26,25
36,0
39,0
40,36
Nurses
125,75
147,5
156,25
165,15
Social workers
14,5
65,25
98,0
108,5
Psychologists
3,0
26,5
57,25
66,6
Specialists for addictions
36,75
30,5
34,75
34,25
22,25
44,5
39,75
40,85
6,5
20,5
23,0
25,8
2,5
7,0
10,25
12,35
Data of State Mental Health Centre of Lithuania

9. PRESCRIPTION COVERAGE OF PSYCHOTROPICS IN LITHUANIA
Schizophrenia,
schizoaffective disorders
(F20; F25)
Amisulpride
Clozapine
Olanzapine
Risperidone
Flupentixol
Fluphenazine
Haloperidol
Trifluoperazine
Zuclopenthixol
Lithium
Trihexyphenidylum

10. 80 % coverage Schizotypal and delusional disorders (F21 - F29)
Amisulpride
Olanzapine
Risperidone
Haloperidol Fluphenazine
Trifluoperazine Zuclopenthixol
Flupentixol
Citalopran Fluvoxamine Lithium
Amitriptyline Paroxetine Trihexyphenidylum
Fluoxetine Sertraline
Moderate and severe
affective disorders
(F30.2; F31.1-F31.5;
F32.1-F32.3; F33.1-F33.3)
Citalopran Fluvoxamine Fluoxetine
Amitriptyline Paroxetine Sertraline
Haloperidol Trifluoperazine Lithium
Mirtazapine Reboxetine Trihexyphenidylum
Dementia
(F00 (G30); F01-F03)
Amitriptyline Donepezil Melperone
Haloperidol Trifluoperazine Lithium
Memantine Tiapridal Trihexyphenidylum

11. 50 % coverage Organic psychotic disorders (F06) Citalopram Fluoxetine
Fluphenazine
Fluvoxamine
Haloperidol
Mirtazapine
Paroxetine
Trifluoperazine
Sertraline
Lithium
Trihexyphenidylum

12. EUROPE (NORTH AND SOUTH) – N5A ANTIPSYCHOTIC MARKET
Source : IMS Health WinEI Q1/02 (Actual Exchange Rates)
Countries and Panels included :- UK; HOLLAND; SWEDEN; POLAND; DENMARK; IRELAND; CZECH REP; GERMANY; FRANCE; SPAIN; ITALY; SWITZERLAND; AUSTRIA; GREECE; PORTUGAL; BELGIUM

13. NORTH AMERICA – N5A ANTIPSYCHOTIC MARKET
Source : IMS Health WinEI Q1/02 (Actual Exchange Rates)
Countries and Panels included :- USA; CANADA

14. LITHUANIA – N5A ANTIPSYCHOTIC MARKET

15. ATYPICAL ANTIPSYCHOTICS PRESCRIPTION GROWTH OVER TIME
*Market Definition = N5A1 Atypical Antipsychotics
Markets = USA, UK, Canada, Netherlands, Germany, Italy, Japan
Source : IMS Health MIDAS Dataview MAT Q1 2002

16. PRESCRIPTION MARKET SHARE VS. MAIN COMPETITORS
*Market Definition = N5A1 Atypical Antipsychotics
Source : IMS Health MIDAS Dataview MAT Q1 2002

17. PRESCRIPTION COVERAGE EXPENSES IN LITHUANIA

18. IN-PATIENT PSYCHIATRIC TREATMENT IN LITHUANIA
Data of State Mental Health Centre of Lithuania

19. TOTAL NUMBER OF BEDS IN MENTAL HOSPITALS IN LITHUANIA
Data of State Mental Health Centre of Lithuania

20. NUMBER OF DISABLED DUE TO SCHIZOPHRENIA AND MENTAL RETARDATION IN LITHUANIA
Data of State Mental Health Centre